Artificial Intelligence in Genomics Market Report Scope & Overview:

The Artificial Intelligence in Genomics Market was valued at USD 1.39 Billion in 2025 and is estimated at USD 1.86 Billion in 2026. It is projected to reach USD 25.96 Billion by 2035, growing at a CAGR of 34.01% during the forecast period from 2026 to 2035. The market covers software, services, and hardware that apply machine learning, deep learning, and language models to DNA and RNA data. Demand is rising because sequencing now produces far more data than human experts can review, and drug developers, laboratories, and hospitals need faster and more consistent ways to find disease-linked variants and new treatment targets.

North America accounts for the biggest market share of 39.56% in 2025, owing to the presence of extensive research initiatives, significant number of pharmaceutical and biotechnology firms, and early adoption of sequencing in clinics. The Asia Pacific region is the fastest-growing region with a CAGR of 37.89% until 2035 due to the presence of national genome initiatives, increasing funding for precision medicine, and decreasing cost of sequencing resulting in increased volume of data generation in countries like China, India, and Japan. Currently, software dominates the offering mix, whereas services are emerging rapidly.

Market Trends and Insights

Drivers Impact Analysis

Falling Cost of Sequencing a Genome

The price of reading a human genome has dropped sharply over the past decade, and this has changed how often sequencing is used. Hospitals order whole genome tests for rare disease cases, drug developers sequence large trial cohorts, and population studies now cover hundreds of thousands of people. Every new genome adds raw data that must be aligned, filtered, and interpreted, and manual review cannot keep pace. This creates steady demand for software that can call variants, rank them by clinical relevance, and flag likely causes of disease. As sequencing becomes routine, the analysis step is the part of the workflow where most new spending is expected to land.

National Population Genomics Programs

Governments in many countries are funding large sequencing programs to build reference datasets for their own populations. These projects produce genomes together with health records, and the combined data is only useful when advanced analytics can link genetic findings to clinical outcomes. Public funding also supports shared computing platforms that private vendors can connect to. In July 2025, Genomics England reported that its Generation Study is sequencing 100,000 newborn genomes to look for treatable conditions early in life. Programs of this kind give vendors large and well-described datasets, and they set practical standards for how AI tools should be tested before clinical use.

Genomic Foundation Models Entering Production

Foundation models trained on very large sets of DNA, RNA, and protein data can predict how a sequence change affects gene activity, which was difficult with older tools. These models can be adapted to many tasks, such as scoring noncoding variants, predicting regulatory effects, and suggesting drug targets. Vendors are now packaging them into software that laboratories and pharmaceutical teams can use without building models themselves. The shift lowers the skill barrier for buyers and shortens project timelines. As more models reach production quality and gain published validation, they are expected to become standard components of genomic analysis pipelines across research and clinical settings.

Pharmaceutical AI Platform Deals for Target Discovery

Drug developers face high failure rates and rising costs, and many now look to genomic evidence to choose targets with a better chance of success. Medicines supported by human genetic data tend to move forward more often, which makes large genomic datasets valuable for model training. Pharmaceutical companies are signing multi-year agreements with technology providers to build AI platforms on these datasets, and they often invest in data creation as well. These agreements bring predictable revenue to vendors and give them access to expert feedback. The activity is concentrated in North America and Europe, and it is expected to widen as more midsize companies adopt similar approaches.

Demand for Precision Oncology and Rare Disease Diagnosis

Cancer care increasingly relies on tumor sequencing to match patients with targeted treatments, and rare disease clinics depend on genomic testing to end long diagnostic searches. Both areas generate complex reports that require careful interpretation of many variants against changing medical literature. AI tools speed up this review, keep it consistent between cases, and update recommendations as new evidence appears. Health systems value the time saved for scarce genetic specialists, while patients benefit from shorter waits for answers. In January 2025, UK Biobank launched a study measuring up to 5,400 proteins in 600,000 samples, which will add a new layer of data for disease prediction.

Clearer Regulatory Guidance on AI Evidence

Companies need to know how regulators will judge AI models before they commit large budgets to them. Draft and final guidance documents explain what evidence is expected, how model risk should be rated, and how performance should be monitored over time. In January 2025, the U.S. Food and Drug Administration issued draft guidance on using artificial intelligence to support regulatory decisions for drugs and biological products, with a risk-based credibility framework. Clear rules reduce the chance of costly rework during submissions. They also help buyers compare vendors on documented testing, and they favor suppliers that already track model versions, data sources, and human oversight carefully.

Restraints Impact Analysis

Ancestry Bias in Training Data

Most large genomic datasets were built from people of European ancestry, so models trained on them can perform less well for other groups. Variant interpretation may be less accurate, risk scores may be less reliable, and some real disease-causing changes may be labeled uncertain simply because they were rarely seen before. Clinicians and regulators are aware of this gap and ask vendors to show results across populations. Building more diverse datasets takes years of sampling, consent, and curation, so progress is gradual. Until the gap narrows, hospitals and laboratories may limit use of AI tools in settings where the patient mix differs from the training data.

Privacy and Data Sovereignty Rules

The genomic information is unique to an individual and cannot be altered once revealed, and therefore there are stringent policies and regulations that govern the collection and sharing of genomic information. There are laws in many nations that stipulate that genomic information should not leave the borders of the country, and also consent laws vary from region to region. The vendors need to have different deployments, contract review processes, and also know where the genomic data is being analyzed. In May 2026, European Union legislators came to a provisional agreement where they agreed to extend the compliance of high-risk AI system to August 2028.

Slow Clinical Validation and Reimbursement

A model that performs well in research does not always earn trust in a hospital. Clinical validation requires studies on real patients, review by medical experts, and in many cases approval or clearance by a regulator. Payers also need proof that an AI-supported test improves care or lowers cost before they agree to reimburse it. These steps can take several years, and the cost falls on the vendor. Smaller companies find it hard to fund such studies, which limits the number of products that reach routine clinical use. As a result, many tools stay in research and drug discovery settings for longer than early forecasts expected.

Shortage of Clinical Bioinformatics Talent

Using AI in genomics well requires people who understand biology, data science, and clinical practice. Few professionals have all three skill sets, and many organizations compete for them. Laboratories often struggle to hire staff who can validate models, maintain pipelines, and explain results to physicians. Smaller hospitals and research centers in emerging regions face the greatest gap. Vendors try to close it with easier interfaces, training programs, and managed services, but these measures add cost. The talent shortage does not stop adoption, though it slows the pace at which new tools move from pilot projects into daily operations across institutions.

Rising Compute and Storage Costs

Genomic analysis produces very large files, and model training requires heavy graphics processing power. Cloud bills grow quickly when teams run repeated analyses on large cohorts, and long-term storage of raw data adds further cost. Academic groups and small biotechnology firms often have fixed budgets and must narrow the scope of their work. Vendors are improving efficiency through faster algorithms, compressed file formats, and shared computing environments, which helps control spending. Even so, compute cost remains a practical limit on how widely the most advanced models can be applied, especially for organizations that lack negotiated cloud pricing or dedicated infrastructure.

Artificial Intelligence in Genomics Market Segment Analysis

By Component, Software Dominates Artificial Intelligence in Genomics Market; Services to Register Fastest Growth.

Software accounted for 41.55% of the Artificial Intelligence in Genomics Market in 2025. Laboratories and drug developers buy platforms that align reads, call variants, rank findings, and produce reports in one workflow. Software scales across thousands of samples without adding staff, and subscription pricing makes it easy to budget. Once a team builds its pipeline around a platform, switching becomes costly, which keeps customers in place and gives vendors a steady base of recurring revenue from year to year.

Services are expected to grow at a CAGR of 35.63% through 2035. Many hospitals and biotechnology firms lack the data scientists needed to prepare datasets, tune models, and verify results. They turn to outside experts for custom pipelines, model validation, regulatory documentation, and clinical interpretation support. As organizations move from pilots to daily use, the need for ongoing help with training and monitoring grows, and managed offerings are replacing one-time projects as the preferred buying model for many large customers.

By Technology, Machine Learning Dominates Artificial Intelligence in Genomics Market; Natural Language Processing to Register Fastest Growth.

Machine learning held 63.43% of the market in 2025. Its methods are the most mature in genomics, covering variant classification, expression prediction, and patient grouping. Researchers have many open datasets and tested algorithms to build on, and laboratories can integrate these tools into existing pipelines with limited change. Results are measurable against known benchmarks, which helps with validation and peer review. Deep learning models, a subset of the same family, are spreading quickly for sequence-level prediction and imaging-linked tasks.

Natural language processing is projected to grow at a CAGR of 35.94% through 2035. Genomic findings depend on medical literature, clinical notes, and trial records that exist mostly as free text. Language models can read these sources, extract gene-disease links, and keep variant classifications current as new papers appear. They also help clinicians query results in plain language. As large language models improve and gain safeguards, vendors are adding them to interpretation tools and research assistants across the industry.

By Functionality, Genome Sequencing Dominates Artificial Intelligence in Genomics Market; Gene Editing to Register Fastest Growth.

Genome sequencing represented 44.36% of the market in 2025. Every genomic workflow begins with reading DNA, and AI is now embedded in the steps that follow, including base calling, alignment, variant detection, and annotation. Wider use of sequencing in cancer care, rare disease testing, and large cohort studies sustains the volume of data requiring analysis. Because sequencing is the entry point, demand for supporting software and compute grows with every new instrument installed in a laboratory, hospital, or research center.

Gene editing is expected to expand at a CAGR of 34.31% through 2035. Therapy developers use AI to design guide sequences, predict unwanted cuts at other sites in the genome, and rank candidate edits before laboratory work begins. This saves months of experiments and lowers cost. Approvals of gene-edited medicines and a growing clinical pipeline are drawing in new funding, which supports demand for design software, safety prediction models, and analysis of editing outcomes in both research and clinical programs.

By Application, Drug Discovery and Development Dominates Artificial Intelligence in Genomics Market; Precision Medicine to Register Fastest Growth.

Discovery and Development of Drugs was expected to account for a 33.99% market share in 2025. Genomic AI is being used to discover the targets and patient populations that might benefit along with reducing failures of drug development. Genetic data is associated with clinical success rates. Hence, pharmaceutical and biotech companies are investing more on building big data and models. Drug developers have a bigger budget for research compared to most clinical buyers and hence can adapt to technologies faster and at larger scales than most clinical buyers.

Precision Medicine is expected to register a CAGR of 36.45% between 2025 and 2035. Health care providers are adopting therapies based on their genetic make-up for various diseases such as cancer treatment as well as dosing of medicines. AI facilitates converting of complex test data to easy to understand recommendations for physicians. Cheaper testing costs, insurance coverage for selected tests, and national programs for sequencing of patients' genes are making more patients eligible and thus increasing adoption in clinical, lab, and public health sectors.

By End User, Pharmaceutical and Biotechnology Companies Dominate Artificial Intelligence in Genomics Market; Clinical Laboratories and Diagnostic Centers to Register Fastest Growth.

Pharmaceutical and biotechnology companies accounted for 38.22% of the market in 2025. They have the research budgets, data assets, and technical teams needed to use advanced models at scale. Large firms run internal AI groups and also sign partnerships with specialist vendors to extend their reach. Their needs span target discovery, biomarker selection, trial design, and companion diagnostics, which means each company buys several tools and often purchases enterprise-wide licenses, with multi-year contracts that cover many research sites.

Clinical laboratories and diagnostic centers are expected to grow at a CAGR of 35.17% through 2035. Test volumes are rising as more physicians order sequencing, and laboratories need automated interpretation to keep turnaround times short. AI tools help reduce manual variant review and improve consistency between analysts. Cloud-based services let smaller laboratories adopt these capabilities without large capital spending, and accreditation bodies increasingly accept documented software pipelines as part of quality systems, which builds confidence in automated workflows.

Geography Analysis

North America Artificial Intelligence in Genomics Market

North America led the global market with a 39.56% share in 2025. The United States accounts for most regional activity, with a market value of USD 485.93 Million in 2025 and a projected CAGR of 34.63%. The country hosts the largest cluster of sequencing companies, genomic data platforms, and pharmaceutical research teams, along with strong venture funding for AI-driven drug discovery. Academic medical centers and cancer hospitals adopt new interpretation tools early. Canada adds demand through its genomic research networks and public health system pilots in several provinces.

Large public datasets support the region's lead. In June 2026, the National Institutes of Health reported that its All of Us Research Program held more than 535,000 whole genome sequences linked to health records, giving researchers a rare resource for model training. Vendors that can work with such datasets, meet privacy rules, and show clinical validation have an advantage. The region is expected to remain the largest market through 2035, though its share will ease as Asia Pacific and Europe expand their own programs.

Europe Artificial Intelligence in Genomics Market

Europe is the second largest regional market, supported by research strength in Germany, the United Kingdom, France, and Switzerland. Germany is the leading country in the region, helped by its pharmaceutical industry and growing use of genomic testing in cancer care. Britain's National Health Service links its sequencing programs to long-running population biobanks, which creates a strong base for disease prediction research. Public health systems fund large sequencing projects and give approved researchers access to well-described data. Close links between hospitals and universities help move findings into practice.

Cross-border cooperation is a defining feature of the region. The 1+ Million Genomes initiative endorsed its 2023 to 2027 roadmap in November 2023, aiming to link national genomic databases under shared standards so researchers can analyze data across countries. This creates demand for federated analysis tools that work without moving records. At the same time, strict data protection and AI rules require careful design, and vendors that document their models and data sources well are better placed to win public sector and hospital contracts.

Asia Pacific Artificial Intelligence in Genomics Market

Asia Pacific is the fastest growing region, with a CAGR of 37.89% through 2035. China is the leading country, supported by large sequencing capacity, national funding for biotechnology, and many local AI developers. Japan and South Korea add demand through advanced hospitals and strong electronics and computing industries, while Australia has created a national agency, Genomics Australia, to coordinate genomic medicine. Cost advantages in sequencing and a growing pool of data scientists make the region attractive for both local and global vendors.

India is building a national reference dataset for its diverse population. In January 2025, the GenomeIndia project released genome data from 10,000 individuals through the Indian Biological Data Centre, with participation from more than 20 institutions. Such resources help correct the shortage of non-European data and give local developers material for training models. Differences in privacy rules and infrastructure across countries remain a challenge, so vendors often partner with local hospitals and laboratories to meet regulatory needs and language requirements.

Middle East & Africa Artificial Intelligence in Genomics Market

The Middle East & Africa is smaller but is building a genomics capability as a part of their health and economic strategy. Leading country in the region is Saudi Arabia, where the national genome initiative created the Saudi pangenome based on samples collected from people living in five different areas, and presented in March 2025. The presence of high frequencies of diseases caused by genetic factors due to specific patterns of family marriages in several Gulf countries makes screening an important public health need and AI technologies help laboratories cope with increased workload without enough specialists.

In UAE, the national Emirati Genome Programme is led by the Abu Dhabi authorities in health and aimed at creating a reference data source for the country's population and promoting collaboration with foreign companies. In Africa, the development of genomic technologies is mainly happening through research projects and public health laboratories with unequal access to computational resources and specialists. The vast majority of programs have international partners in terms of technological solutions and training but the demand is likely to increase gradually from the current low levels.

Latin America Artificial Intelligence in Genomics Market

Latin America, which includes Mexico, is an emerging market with growing interest in genomic medicine. Brazil is the leading country, supported by the region's largest healthcare system, strong public research universities, and established cancer and rare disease centers. Mexico, Argentina, and Colombia are developing sequencing services in major cities and taking part in international research studies and trials. Multinational drug developers are also running trials in the region, which creates a need for data analysis tools and local expertise in interpretation.

Brazil's Ministry of Health supports the Genomas Brasil program, which aims to build a national genomic database and extend precision health services within the public system. Projects of this kind could provide the data needed to train models that suit the region's mixed ancestry. Budget limits, currency swings, and uneven laboratory infrastructure remain challenges. Cloud-based services offer a practical path for smaller institutions, because they reduce upfront investment and allow access to advanced software without maintaining large computing systems on site.

Competitive Landscape

The Artificial Intelligence in Genomics Market is fragmented. Sequencing instrument makers, clinical genomics companies, AI drug discovery firms, and cloud data platform providers all compete for parts of the same workflow, and no single vendor controls the full chain from sample to decision. Larger companies compete through data assets, installed instrument bases, and clinical relationships. Smaller firms stand out through specialized models, faster deployment, and strength in one disease area or one step of interpretation, which also makes them frequent acquisition targets.

Strategy in the market follows several clear lines. Vendors are acquiring interpretation and decision-support companies to add clinical depth, building proprietary datasets to train models, and forming partnerships with pharmaceutical firms for target discovery. Many are also launching federated and secure research platforms so that institutions can analyze data without moving it. Strong clinical validation, transparent documentation, and compliance with regional privacy rules are becoming important factors in winning hospital and pharmaceutical contracts.

Companies Covered in this Report

• Tempus AI

• QIAGEN

• Illumina

• SOPHiA GENETICS

• GeneDx

• SeqOne

• Lifebit

• BenevolentAI

Scope and Research Methodology

The Artificial Intelligence in Genomics Market study covers software platforms, services, and supporting hardware that apply machine learning, deep learning, and natural language processing to genomic data. This includes sequence analysis, variant interpretation, gene editing design, and clinical workflow tools used in drug discovery, diagnostics, and precision medicine. The base year is 2025 and the forecast period runs from 2026 to 2035. All values are stated in USD and reflect revenue earned from AI software, subscriptions, related services, and dedicated hardware. The market is segmented by component, technology, functionality, application, end user, and region, and each segment is sized and forecast separately.

The research program begins with secondary research. Analysts review company annual reports, investor presentations, and regulatory filings, along with government health agency databases, national genome program publications, scientific journals, patent records, trade association data, and product documentation. This work maps the vendor landscape, product portfolios, pricing approaches, adoption patterns, and the policy events that shape demand. Historical data for 2020 to 2024 is compiled to establish growth trends. Primary research follows. Structured interviews and surveys with senior executives, bioinformatics and data science leaders, laboratory directors, clinical geneticists, and technology specialists across the value chain are used to validate assumptions on adoption, pricing, and spending priorities. These discussions also test the forecast against real purchasing plans.

Market engineering combines two approaches. A bottom-up build starts from vendor revenue, product adoption, and sequencing activity, and it is cross-checked top-down against research and development spending, genomic testing volumes, and health technology investment. Data triangulation compares the results of both methods with primary findings, and differences are resolved through follow-up validation. The forecast model reflects falling sequencing costs, advances in model performance, regulatory change, funding for national genome programs, and macroeconomic conditions. Every estimate passes a quality review by senior analysts for consistency, logic, and completeness before it is included in the report. Assumptions are documented and updated as new company disclosures and regulatory announcements become available.

Artificial Intelligence in Genomics Market Report Scope: